Neurosensory account of anxiety and stress — experiment 2
Official title: Threat-related Sensory Cortical (SC) Disinhibition and SPA Pathology in Posttraumatic Stress Disorder (PTSD) (Aim 3; Expts. 2&3)
Run by The University of Texas Health Science Center, Houston · NCT07079839 · Data updated 2026-11-12
This trial tests whether a mild, noninvasive brain stimulation (tACS) tuned to each person's alpha rhythm can change brain activity and reduce anxious arousal and hypervigilance in adults with PTSD compared with sham and random-noise stimulation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | July 3, 2025 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT07079839 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are right-handed adults aged 18–50 with a PTSD diagnosis, normal or corrected vision and normal smell, who meet tACS safety screening and have stable psychotropic medications for at least two months if medicated.
✕Probably not a fit
Patients with major medical or neurological illnesses, a history of seizures or serious head injury, or who fall outside the age or sensory/handedness criteria are unlikely to be eligible and therefore would not benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The investigators will recruit 80 adults with PTSD and 80 healthy controls and randomly assign participants, double-blind, to active tACS at individual alpha peak frequency, sham tACS, or active control transcranial random noise stimulation (tRNS). Participants complete simultaneous EEG/fMRI and behavioral testing before and after stimulation while performing a visual search task and an olfactory detection task that include threat and neutral stimuli. Stimulation electrodes are placed in holders on an EEG cap to permit concurrent recording, and the protocol tests a proposed Sensory-Prefrontal-Cortex-Amygdala (SPA) model of threat-related sensory cortical disinhibition and PTSD pathophysiology. The design aims to link neural changes with behavioral markers of anxious arousal and hypervigilance and to compare tACS effects to sham and active control stimulation.
Why it matters
Potential benefit: If successful, the approach could point to a noninvasive way to normalize sensory–prefrontal–amygdala network activity and reduce hypervigilance and anxious arousal in people with PTSD.
How similar studies have gone: Related noninvasive brain stimulation approaches such as rTMS and tDCS have shown preliminary promise for anxiety and PTSD symptoms, but tACS is less well tested and evidence is currently limited and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Right-handed * With normal or corrected-to-normal vision and normal olfaction * Between the ages of 18 and 50 years * Meeting the tACS screening criteria (see List I below; e.g., lack of a serious head injury or loss of consciousness) * Patients: Diagnosis of PTSD * Patients: If taking psychotropic medications, medication stability in the past 2 months * If having mild substance use disorder (for patients) or occasional substance use, abstention from use 48 hours before the experiment. Exclusion Criteria: * A history of diagnosis for a major medical illness (e.g., cancer, metabolic syndrome, cardiovascular disease, inflammatory disorders) or a neurological disorder (e.g., seizure, stroke, Parkinson's disease). * Patients: Concurrent Axis I diagnosis (depression, anxiety, and mild substance use disorder are allowed given their high comorbidity with PTSD). * Healthy controls: A history of diagnosis for a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Axis I disorder or current use of psychoactive medications. * Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior that poses an immediate danger to self or others. * History of head trauma with unconsciousness (\> 5 minutes) * Report that they regularly drink 3 or more alcoholic beverages a day. * Report that they are unable to abstain from substance use (including alcohol, nicotine, cannabis, amphetamines, narcotics, solvents, cocaine, hallucinogens, tranquilizers, barbiturates, etc.) or sleep medication for 48 hours before being scanned. * Are on calcium channel blockers (e.g., verapamil, nifedipine) or alpha-blockers (e.g., prazosin, terazosin) and are unable to stop these medications for a 48-hour period prior to scanning (to exclude the impact of these medications on the interpretation of fMRI/EEG). * Failed Urine Drug Screening Test: A rapid urine screening test that utilizes monoclonal antibodies to detect elevated levels of specific drugs (including alcohol, amphetamines, benzodiazepines, barbiturates, cocaine, marijuana, opiates, etc.) in urine (iCup) * Pregnancy based on urine test. The safety of magnetic resonance (MR) systems has not been established for fetuses * Having electrically, magnetically, or mechanically activated implants (e.g., cardiac pacemakers), because the electromagnetic fields produced by the MR system may interfere with the operation of these devices.
Where it's running
-
The University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Wen Li, PhD — The University of Texas Health Science Center, Houston
- Study coordinator: Wen Li, PhD
- Email: Wen.Li.1@uth.tmc.edu
- Phone: (713) 486-2700
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep Brain Reorienting for PTSD in Veterans
This study tests whether Deep Brain Reorienting can help reduce PTSD symptoms in military veterans compared with usual care.
-
Trauma recovery options for veterans: comparing HRV biofeedback and present-centered therapy
This trial tests whether Heart Rate Variability Biofeedback plus trauma-informed care helps veterans with PTSD and substance use issues more than present-centered therapy.
-
CIDI 5.0 validation against SCID-5 for lifetime mental disorders in Hong Kong adults
This study tests whether the CIDI 5.0 interview can reliably identify lifetime mental disorders in adults in Hong Kong by comparing it with the SCID-5 diagnostic interview.
-
Two-week intensive outpatient trauma program for PTSD
This program will test whether a two-week outpatient course combining Prolonged Exposure and EMDR reduces PTSD symptoms and improves functioning in adults with PTSD.
-
Side-by-Side Testing of SPARCS and the Unified Protocol for Youth with Chronic Illness and Trauma
This trial tests whether two trauma-focused therapies (SPARCS and the Unified Protocol) help kids and teens with chronic medical conditions feel less trauma-related distress and function better, delivered in group or individual formats.
-
Metacognitive Therapy vs Cognitive-Behavioral Therapy for Anxiety Disorders
This study asks people with generalized anxiety disorder, social anxiety disorder, or PTSD to share their experiences after trying metacognitive therapy or disorder-specific cognitive-behavioral therapy in a randomized trial.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.